Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy

[1]  G. Moneta.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions Heart , 2022 .

[2]  D. Mikhailidis,et al.  Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects , 2005, Stroke.

[3]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[4]  Paul Schoenhagen,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.

[5]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[6]  B. Psaty,et al.  Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups , 2004, Neurology.

[7]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[8]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[9]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[10]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[11]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[12]  J. Michael Gaziano,et al.  Cholesterol and the Risk of Ischemic Stroke , 2003, Stroke.

[13]  M. Hennerici,et al.  Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2003, Cerebrovascular Diseases.

[14]  N. Poulter,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial☆ , 2003 .

[15]  N J Wald,et al.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[16]  M. Ezekowitz,et al.  Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy , 2002, Circulation.

[17]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[18]  J. Liao.  Statins and ischemic stroke. , 2002, Atherosclerosis. Supplements.

[19]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[20]  P. Ridker,et al.  Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆ , 2001 .

[21]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[22]  B. Davis,et al.  Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.

[23]  R. Westendorp,et al.  C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[24]  E. Ford,et al.  Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[25]  A. Brett.  Pravastatin therapy and the risk of stroke. , 2000, The New England journal of medicine.

[26]  E. Ford,et al.  Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: findings from National Health and Nutrition Examination Survey III. , 2000, Journal of clinical epidemiology.

[27]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[28]  B. Davis,et al.  Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. , 1999, Circulation.

[29]  M. Pfeffer,et al.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. , 1999, Circulation.

[30]  C. Furberg,et al.  HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. , 1998, Atherosclerosis.

[31]  G. Guyatt,et al.  Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. , 1998, Annals of internal medicine.

[32]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[33]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[34]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[35]  D. Kromhout.  Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[36]  D. Reed,et al.  Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. , 1989, Stroke.

[37]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.